Stocktoria
Corbus Pharmaceuticals Holdings, Inc. CRBP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-10-24
Corbus Pharmaceuticals Holdings, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $881,705 |
| R&D expense | $70.1M | $32.2M | $31.2M | $16.1M | $36.4M |
| Operating income | -$85.3M | -$48.7M | -$45.1M | -$39.8M | -$56.0M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$78.5M | -$40.2M | -$44.6M | -$42.3M | -$45.6M |
| EPS (diluted) | $-5.90 | $-3.68 | $-10.31 | $-10.15 | $-11.15 |
| Operating cash flow | -$64.5M | -$41.8M | -$36.1M | -$37.5M | -$48.2M |
| Free cash flow | -$64.5M | -$41.8M | -$36.1M | -$37.6M | -$48.2M |
| Cash & equivalents | $28.5M | $17.2M | $13.7M | $17.0M | $25.0M |
| Total assets | $168.2M | $155.9M | $28.3M | $66.3M | $107.7M |
| Total liabilities | $20.7M | $13.5M | $35.2M | $33.3M | $38.6M |
| Shareholders' equity | $147.5M | $142.4M | -$6.9M | $33.0M | $69.1M |
Source: SEC EDGAR filings · CIK 0001595097 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.